Cell Biology Program
The Xuejun Jiang Lab
Research

Professor
The research of my laboratory focuses on two directions highly relevant to cancer biology, (1) the molecular basis of programmed cell death processes (including apoptosis and ferroptosis), and their roles in human disease; and (2) the molecular basis of autophagy and its role in cancer. We also study various cancer signaling and cellular metabolic events, especially those involved in cell death/survival determination. We aim to translate our basic research finding into potential therapeutic approaches. To achieve these goals, the laboratory utilizes a combination of approaches including biochemistry, chemical biology, proteomics, molecular cell biology, high-throughput screening, 3-dimensional microfluidic cell array, and mouse modeling.

Featured News



Publications Highlights
People

Xuejun Jiang, PhD
Virginia and Daniel K. Ludwig Chair 1
Professor
- Cell biologist Xuejun Jiang studies programmed cell death, molecular mechanisms, and their roles in tumorigenesis.
- PhD, University of Texas Southwestern Medical Center at Dallas
- [email protected]
- Email Address
- 212-639-6814
- Office Phone
Members





- 212-639-7339
- Lab Phone




Research Fellow

Graduate Student, Tri-I PhD Program in Chemical Biology

Graduate Student, GSK

Administrative Assistant, Sr.

Graduate Student, GSK

Graduate Student, Tri-I PhD Program in Chemical Biology

Lab Head

Graduate Student, WCMC

Research Fellow

Research Scholar

Graduate Student, Tri-I PhD Program in Chemical Biology

Senior Research Scientist
Research Scholar









- University of Georgia


- PhD, Nankai University, China






Lab Alumni

University Assistant at Johannes Kepler University

Scientist, International Flavors & Fragrances

Principal Scientist, Accutar Therapeutics

Group Leader - Reader, The University of Edinburgh
Programme Leader at MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee

Principal Investigator and Professor, Harbin Institute of Technology
Associate Professor, Department of Biochemistry and Molecular Biology, Penn State Cancer Institute
Research Scientist, MSKCC
Postdoc Research Fellow at Ben Gurion University of the Negev, Israel

Manager of Regulatory Affairs Strategy, Regeneron Pharmaceuticals, Inc.

Assistant Investigator, Chinese Institutes for Medical Research Beijing

Scientist, Lime Therapeutics

Principal Scientist at Wave Life Sciences, Boston, MA

Freelance, Medical Communications Consultant
President and Founder of Bon Opus Biosciences

R&D Director, HydroGene Therapeutics
Vice Director at Zhangjiagang Hospital

Drug Discovery Scientist, Bristol Myers Squibb

Principal Investigator, Peking University International Cancer Center

Principal Investigator at Roswell Park Cancer Institute

Graduate Student, SUNY Downstate Health Sciences University

Innovative Cell biology Researcher at National Singapore University

Professor at Fourth Military Medical University, Xi'an

Program Manager at Center Ministry of Science and Technology, China
Professor at Air Force Military Medical University, China

Graduate Student, WCMC

Exchange Graduate Student
Lab Affiliations
Achievements
- Louis and Allston Boyer Young Investigator Award for Basic Research, Memorial Sloan Kettering Cancer Center (2007)
- Scholar, American Cancer Society (2007-2010)
- Catherine and Frederick Adler Chair for junior faculty, Memorial Sloan Kettering Cancer Center (2006)
- V Scholar, The V Foundation for Cancer Research (2004-2006 )
- Alfred Bressler Scholar, Alref W. Bresller Scholars Fund (2004-2007)
Read more
- Sigma Xi Award, UT Southwestern (1998)
- Robert A. Welch Predoctoral Fellowship, UT Southwestern (1995-1999)
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Get in Touch
-
Lab Head Email
-
Office Phone
-
Office Fax
-
Lab Phone
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Xuejun Jiang discloses the following relationships and financial interests:
-
Exarta Therapeutics
Equity; Fiduciary Role / Position; Intellectual Property Rights; Professional Services and Activities -
Lime Therapeutics, Inc.
Equity; Professional Services and Activities (Uncompensated)
-
VivoZ Biolabs, LLC
Intellectual Property Rights; Professional Services and Activities (Uncompensated)
The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2023 through disclosure submission in spring 2024). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].